Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

Dr Anish Shah

FDA_Approved
August 14, 2023
New Approvals/New Drug Applications

FDA Approves Talquetamab-Tgvs For Adults with Relapsed Or Refractory Multiple Myeloma Patients with at least Four Prior Lines of Therapy

By Dr. Anish Shah Bronx Lebanon Hospital   On August 9, 2023, the U.S. Food and Drug Administration approved talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with multiple myeloma with relapsed or

FDA_Approved
New Approvals/New Drug Applications

FDA approves niraparib and abiraterone acetate plus prednisone for metastatic prostate cancer With BRCA Mutation

By Dr. Anish Shah Bronx Lebanon Hospital   On August 11, 2023, the U.S. Food and Drug Administration granted regular approval to niraparib and abiraterone acetate (Akeega) plus prednisone for adult patients with metastatic castration-resistant prostate cancer (mCRPC) with deleterious

August 15, 2023

FDA Approves Elranatamab-bcmm for Multiple Myeloma with Relapsed or Refractory Status

New Approvals/New Drug Applications

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm (Elrexfio) for

FDA Approves HEPZATO KIT for Uveal Melanoma with Unresectable Hepatic Metastases

New Approvals/New Drug Applications

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 14, 2023, the U.S. Food and Drug Administration approved HEPZATO KIT – which is melphalan,

FDA_Approved
New Approvals/New Drug Applications

FDA Approves HEPZATO KIT for Uveal Melanoma with Unresectable Hepatic Metastases

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 14, 2023, the U.S. Food and Drug Administration approved HEPZATO KIT – which is melphalan, as a liver-directed treatment for adult patients with

More
by Staff Writer - The Cancer News
August 17, 2023
FDA_Approved
New Approvals/New Drug Applications

FDA Approves Elranatamab-bcmm for Multiple Myeloma with Relapsed or Refractory Status

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm (Elrexfio) for adults with relapsed or refractory multiple myeloma who

More
by Staff Writer - The Cancer News
August 17, 2023
FDA_Approved
New Approvals/New Drug Applications

FDA approves niraparib and abiraterone acetate plus prednisone for metastatic prostate cancer With BRCA Mutation

By Dr. Anish Shah Bronx Lebanon Hospital   On August 11, 2023, the U.S. Food and Drug Administration granted regular approval to niraparib and abiraterone acetate (Akeega) plus prednisone for adult patients

More
by Staff Writer - The Cancer News
August 15, 2023
FDA_Approved
New Approvals/New Drug Applications

FDA Approves Talquetamab-Tgvs For Adults with Relapsed Or Refractory Multiple Myeloma Patients with at least Four Prior Lines of Therapy

By Dr. Anish Shah Bronx Lebanon Hospital   On August 9, 2023, the U.S. Food and Drug Administration approved talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with multiple myeloma with relapsed or

More
by Staff Writer - The Cancer News
August 14, 2023

your advertisement here

you may also like...

  • FDA Approves Luspatercept-aamt for Anemia in Patients with Myelodysplastic Syndromes
  • Overview of KEYNOTE-671 & NADIM II
  • Expert Opinion: Children’s Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse
  • FDA_Approved
    FDA Approves HEPZATO KIT for Uveal Melanoma with Unresectable Hepatic Metastases
  • FDA_Approved
    FDA Approves Elranatamab-bcmm for Multiple Myeloma with Relapsed or Refractory Status

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conference Coverage
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Approvals
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

ASCO ASCO23 award Binaytara foundation breast cancer BTF cancer cancer care cancer disparities cancer research cancer survival cancer treatment Cellular therapy CME conference Conferences continuing education Dr. Binay Shah Dr Anish Shah Dr Shipra Gandhi Expert Opinion faculty highlight FDA FDA Approval FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies hematologic malignancies leukemia Lung cancer lymphoma multiple myeloma Nepal cancer care oncology CME SCHD video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article